Profile data is unavailable for this security.
About the company
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. It is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. It is developing bioelectronic therapies based on patented CNT technology. BackBeat CNT, also known as Atrioventricular Interval Modulation (AVIM) therapy, is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
- Revenue in USD (TTM)2.22m
- Net income in USD-51.64m
- Incorporated2023
- Employees56.00
- LocationOrchestra Biomed Holdings Inc150 Union Square DriveNEW HOPE 18938United StatesUSA
- Phone+1 (646) 343-9298
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| InfuSystem Holdings Inc | 127.41m | 84.00k | 137.14m | 499.00 | 2,316.55 | 2.62 | 11.16 | 1.08 | 0.0028 | 0.0028 | 5.91 | 2.46 | 1.23 | 10.66 | 6.57 | 255,330.70 | 0.0811 | 4.60 | 0.0955 | 5.69 | 50.27 | 56.43 | 0.0659 | 4.07 | 1.51 | 1.56 | 0.3641 | 0.00 | 14.44 | 13.38 | 4,744.44 | -- | 6.01 | -- |
| Akoya Biosciences Inc | 93.57m | -68.01m | 140.62m | 330.00 | -- | 4.30 | -- | 1.50 | -1.47 | -1.47 | 1.99 | 0.6632 | 0.6056 | 2.20 | 7.08 | 283,554.50 | -44.01 | -- | -56.06 | -- | 55.99 | -- | -72.68 | -- | 2.38 | -10.15 | 0.7013 | -- | 29.09 | -- | 10.36 | -- | -- | -- |
| Electromed Inc | 53.50m | 4.36m | 141.78m | 170.00 | 33.14 | 3.33 | 27.39 | 2.65 | 0.4942 | 0.4942 | 6.08 | 4.92 | 1.17 | 3.31 | 2.25 | 314,682.30 | 9.49 | 7.86 | 11.03 | 9.14 | 76.41 | 76.25 | 8.14 | 7.38 | 5.87 | -- | 0.00 | 0.00 | 15.38 | 11.17 | 37.35 | 11.00 | 24.58 | -- |
| TELA Bio Inc | 63.15m | -40.30m | 154.83m | 227.00 | -- | 10.76 | -- | 2.45 | -1.67 | -1.67 | 2.61 | 0.5834 | 0.9668 | 1.37 | 7.60 | 278,180.60 | -61.70 | -52.00 | -79.77 | -60.95 | 68.97 | 65.32 | -63.82 | -107.65 | 3.23 | -8.52 | 0.7387 | -- | 41.13 | 47.85 | -5.35 | -- | -17.12 | -- |
| Accuray Inc | 430.55m | -21.49m | 161.77m | 1.02k | -- | 3.94 | -- | 0.3757 | -0.2197 | -0.2197 | 4.42 | 0.4139 | 0.9178 | 1.86 | 5.72 | 420,462.90 | -4.58 | -1.45 | -7.84 | -2.48 | 33.06 | 37.86 | -4.99 | -1.62 | 0.778 | -0.3857 | 0.8086 | -- | 4.12 | 2.03 | -73.56 | -- | 13.92 | -- |
| Semler Scientific Inc | 65.88m | 21.69m | 162.58m | 92.00 | 8.28 | 2.04 | 7.28 | 2.47 | 2.78 | 2.78 | 8.45 | 11.26 | 0.855 | 15.13 | 8.51 | 716,097.80 | 28.14 | 38.83 | 31.14 | 44.41 | 89.43 | 90.22 | 32.92 | 32.58 | 12.11 | -- | 0.00 | -- | 20.28 | 25.98 | 43.69 | 32.64 | -0.3821 | -- |
| Clearpoint Neuro Inc | 26.16m | -20.63m | 170.01m | 107.00 | -- | 4.92 | -- | 6.50 | -0.8326 | -0.8326 | 1.05 | 1.26 | 0.5037 | 1.26 | 10.08 | 244,495.30 | -39.71 | -34.75 | -49.90 | -39.67 | 57.10 | 64.75 | -78.84 | -76.91 | 2.61 | -- | 0.2237 | -- | 16.56 | 26.64 | -34.40 | -- | 75.30 | -- |
| Stereotaxis Inc | 27.10m | -21.22m | 172.47m | 122.00 | -- | 11.84 | -- | 6.36 | -0.2575 | -0.2575 | 0.3288 | 0.2439 | 0.6012 | 1.45 | 6.14 | 222,155.70 | -44.08 | -25.02 | -63.05 | -34.12 | 55.16 | 67.57 | -73.32 | -41.90 | 1.79 | -- | 0.00 | -- | -4.89 | -1.82 | -12.33 | -- | 6.63 | -- |
| CVRx Inc | 42.09m | -52.01m | 179.03m | 200.00 | -- | 2.70 | -- | 4.25 | -2.48 | -2.48 | 2.01 | 3.07 | 0.3678 | 0.6781 | 5.64 | 210,430.00 | -45.45 | -- | -48.95 | -- | 84.45 | -- | -123.58 | -- | 10.87 | -21.11 | 0.3064 | -- | 74.89 | -- | 0.5528 | -- | -- | -- |
| Orchestra Biomed Holdings Inc | 2.22m | -51.64m | 186.45m | 56.00 | -- | 3.26 | -- | 84.14 | -1.47 | -1.47 | 0.063 | 1.60 | 0.0203 | 1.01 | 30.99 | 39,571.43 | -47.18 | -- | -52.58 | -- | 92.06 | -- | -2,330.46 | -- | 7.33 | -- | 0.00 | -- | -21.88 | -- | -37.91 | -- | -- | -- |
| Outset Medical Inc | 125.08m | -168.77m | 186.64m | 480.00 | -- | 2.00 | -- | 1.49 | -3.38 | -3.38 | 2.50 | 1.80 | 0.3529 | 1.82 | 3.53 | 260,577.10 | -47.61 | -41.40 | -54.98 | -47.29 | 24.61 | 5.71 | -134.93 | -159.05 | 5.32 | -32.13 | 0.6786 | -- | 13.00 | 130.43 | -6.04 | -- | 14.27 | -- |
| Inogen Inc | 321.52m | -96.68m | 208.19m | 834.00 | -- | 1.08 | -- | 0.6475 | -4.15 | -4.15 | 13.81 | 8.15 | 0.917 | 6.03 | 6.83 | 385,519.20 | -27.57 | -8.23 | -34.28 | -9.53 | 40.54 | 44.54 | -30.07 | -10.31 | 2.36 | -- | 0.00 | -- | -16.32 | -2.49 | -22.30 | -- | 26.34 | -- |
| Delcath Systems Inc | 4.61m | -49.79m | 210.33m | 76.00 | -- | 13.17 | -- | 45.65 | -2.65 | -2.65 | 0.2357 | 0.5747 | 0.1382 | 0.4545 | 4.56 | 60,618.42 | -149.30 | -116.57 | -249.28 | -243.21 | 70.54 | 71.02 | -1,080.73 | -1,235.37 | 2.25 | -42.25 | 0.3348 | -- | -24.05 | -9.53 | -30.60 | -- | -5.26 | -- |
| Butterfly Network Inc | 68.08m | -121.92m | 217.03m | 225.00 | -- | 1.06 | -- | 3.19 | -0.5893 | -0.5893 | 0.329 | 0.9685 | 0.2045 | 0.6954 | 4.97 | 302,577.80 | -36.61 | -- | -42.07 | -- | 26.50 | -- | -179.08 | -- | 3.34 | -- | 0.00 | -- | -10.21 | -- | 20.76 | -- | -- | -- |
| Neuropace Inc | 69.07m | -31.51m | 235.04m | 171.00 | -- | 16.36 | -- | 3.40 | -1.18 | -1.18 | 2.59 | 0.4994 | 0.6735 | 1.62 | 6.63 | 403,935.70 | -30.72 | -- | -34.60 | -- | 73.97 | -- | -45.61 | -- | 5.56 | -4.67 | 0.8019 | -- | 43.72 | -- | 30.00 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Orchestra Biomed Holdings Inc's reporting currency: US Dollar USD
34.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 31 Mar 2024 | 5.62m | 15.71% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 2.55m | 7.12% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.19m | 3.34% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 851.84k | 2.38% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 558.82k | 1.56% |
| BlackRock Advisors LLCas of 31 Mar 2024 | 542.08k | 1.52% |
| Geode Capital Management LLCas of 31 Mar 2024 | 440.10k | 1.23% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 254.95k | 0.71% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 179.71k | 0.50% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 140.04k | 0.39% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
